#granules can be added on dips till 160 and on the upper side it seems 210/230/250 🙂
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
GRANULES Share Price Discussion
Granules India Ltd.
NSE: GRANULES | BSE: 532482 | ISIN: INE101D01020 | Sector: Pharmaceuticals and health care
GRANULES Rating
- ★★
- ★★
- ★★
- ★★
- ★★
4.9/5 (8 Ratings)
GRANULES Share Price *
184.35 -3.6 (-1.92%)
* (quote may be delayed)
Find answers to all your questions on live GRANULES message board: Is GRANULES buy or sell? Should I buy GRANULES shares? Why are GRANULES shares falling? Should I invest in GRANULES stock?
You can also check GRANULES share price target recommended by brokerages.
GRANULES Discussion Forum
@researcheducation • Reputation: 10,061
BUY GRANULES INDIA CMP 188
ONLY NEAR 160 - 140 START
SUPPORT - 120
TARGET - 240 250 260 ++
Like
reply
Reply
@researcheducation • Reputation: 10,061
BUY GRANULES INDIA CMP 188
ONLY NEAR 140 - 160 START ACCUMULATING
SUPPORT - 120
TARGET - 250 250 260 ++
Like
reply
Reply
@ravikanthchopperla • Reputation: 11,889
Granules India received two observations following completion of the USFDA inspection in Hyderabad unit.
Like
reply
Reply
@hustlewithme • Reputation: 7,328
ＩＣＨＩＭＯＫＵ ＣＨＡＲＴＳ in GRANULES
#granules call given at 127 now at 170 plus . 200 coming soon #ichimoku
Like
reply
Reply
@hustlewithme • Reputation: 7,328
#granules call given at 127 now at 170 plus . 200 coming soon #ichimoku
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India gets tentative nod from USFDA for expectorant tablets
"US Food & Drug Administration (USFDA) has tentatively approved its Abbreviated New Drug Application for Guaifenesin extended-release tablets, 600 mg and 1200 mg (OTC)," the company said in a filing to the BSE.
"US Food & Drug Administration (USFDA) has tentatively approved its Abbreviated New Drug Application for Guaifenesin extended-release tablets, 600 mg and 1200 mg (OTC)," the company said in a filing to the BSE.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India gets tentative nod from USFDA for generic Colchicine capsules
The US Food and Drug Administration (USFDA) has tentatively approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals Inc for Colchicine capsules in the strength of 0.6 mg, Granules India said in a filing to the BSE.
The US Food and Drug Administration (USFDA) has tentatively approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals Inc for Colchicine capsules in the strength of 0.6 mg, Granules India said in a filing to the BSE.
Moneycontrol
Like
reply
Reply
@hustlewithme • Reputation: 7,328
#granules weekly breakout confirmed 165
200 is possible
( self invested in from very lower levels so dont jump blindly #ichimoku #chartsdontlie
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules Pharmaceuticals, Inc gets USFDA nod for Colchicine tablets
Familial mediterranean fever is a genetic disorder that causes recurrent episodes of fever that are typically accompanied by pain in the abdomen, chest, or joints.
Familial mediterranean fever is a genetic disorder that causes recurrent episodes of fever that are typically accompanied by pain in the abdomen, chest, or joints.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India hits 52-week high after USFDA approval
Colchicine tablets are used in the treatment of Familial Mediterranean Fever.
Colchicine tablets are used in the treatment of Familial Mediterranean Fever.
Moneycontrol
Like
reply
Reply
@hustlewithme • Reputation: 7,328
ＩＣＨＩＭＯＫＵ ＣＨＡＲＴＳ in GRANULESGRANULESTrade entered: Buy GRANULES @157.25 Target@200 ...
Granules bought at 157 now 161
Weekly chart breakout on ichimoku
Target 200
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India share price jumps 5% on USFDA nod for antiviral medicine
Domestic brokerage firm Sharekhan by BNP Paribas has maintained a positive view on the stock with an upside potential of 12-15 percent while Anand Rathi Share has a buy recommendation with a target price of Rs 181.
Domestic brokerage firm Sharekhan by BNP Paribas has maintained a positive view on the stock with an upside potential of 12-15 percent while Anand Rathi Share has a buy recommendation with a target price of Rs 181.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India arm gets USFDA nod for Valganciclovir hydrochloride oral solution
"The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc, a-wholly owned foreign subsidiary of Granules India Ltd for Valganciclovir hydrochloride for oral solution, 50 mg/ml," the company said in a regulatory filing.
"The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc, a-wholly owned foreign subsidiary of Granules India Ltd for Valganciclovir hydrochloride for oral solution, 50 mg/ml," the company said in a regulatory filing.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Granules India divests entire stake in Granules-Biocause Pharmaceutical
Last year, Granules India had intimated about the divestment of the entire stake of the JV company for a total consideration of RMB 109 million (around Rs 110.8 crore).
Last year, Granules India had intimated about the divestment of the entire stake of the JV company for a total consideration of RMB 109 million (around Rs 110.8 crore).
Moneycontrol
Like
reply
Reply
@databot • Reputation: 2,050
Geojit Financial Services target on GRANULES
Date: 04-Feb-20
Broker: Geojit Financial Services
Price @ Call: 146.4
Target: 175
Recommendation: BUY
Like
reply
Reply
@ygtrader • Reputation: 1,722
Granules is Recommended to Buy,
Prices broke a long term trendline with high volume,
And prices are ready to make new historical highs,
Buy on dips.
(Every price dip is buying opportunity)
Like
reply
Reply
@newsbot • Reputation: 2,308
Q3 earnings mixed so far; brokerages maintain 'buy' on 10 stocks with 9-23% upside
Last week, FIIs bought equities worth Rs 1,790.6 crore, while Domestic Institutional Investors sold equities worth of Rs 2,620.48 crore
Last week, FIIs bought equities worth Rs 1,790.6 crore, while Domestic Institutional Investors sold equities worth of Rs 2,620.48 crore
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,308
Small & midcaps back in spotlight as FIIs raise stake in 122 BSE companies
Most of the companies in which FIIs raised stake are financially sound, have prudent management but be selective while picking stocks, experts say.
Most of the companies in which FIIs raised stake are financially sound, have prudent management but be selective while picking stocks, experts say.
Moneycontrol
Like
reply
Reply
@databot • Reputation: 2,050
Centrum target on GRANULES
Date: 21-Jan-20
Broker: Centrum
Price @ Call: 146.96
Target: 205
Recommendation: BUY
Like
reply
Reply
@hustlewithme • Reputation: 7,328
GRANULES
One year target
Like
reply
Reply (3)
Latest replies
Sir it looks it will reach in 1 week
@guptan • Reputation: 3,172
GRANULES
Like
reply
Reply (2)
Latest replies
How many days target will reach sir
Weekly some weeks
@databot • Reputation: 2,050
AnandRathi target on GRANULES
Date: 21-Jan-20
Broker: AnandRathi
Price @ Call: 146.96
Target: 181
Recommendation: BUY
Like
reply
Reply
@databot • Reputation: 2,050
Motilal Oswal target on GRANULES
Date: 22-Jan-20
Broker: Motilal Oswal
Price @ Call: 139.65
Target: 165
Recommendation: BUY
Like
reply
Reply
@ravikanthchopperla • Reputation: 11,889
Granules India today announced an interim dividend of Rs0.25 per share. The ex dividend date is Thursday, January 30 and the record date is Friday, January 31, 2020.
1
reply
Reply
@ravikanthchopperla • Reputation: 11,889
Granules India’s Q3 FY20 profit increased 6.1% y/y to Rs 64 crore, while revenue was up 11.4% y/y to Rs 704 crore. The margin expanded 390bps y/y to 21.8%. Also, the board approved share buyback of up to 1.25 crore equity share at Rs 200 per share. The stock closed 5% lower.
Like
reply
Reply
@TTA • Reputation: 23,829
Granules India – Q3 FY20 (Unaudited - Cons)
Share price – 146
Revenue from operations at 703.95 Cr
631.77 Cr (11.82%) YoY | 699.55 Cr (0.55%) QoQ
YTD 9 months ended revenue: 1,999 Cr Vs. 1,666 Cr (19.97%)
Net Profit of 64.02 Cr
60.31 Cr (6.66%) YoY 95.79 (-32.57%) ...
Read more...
Like
reply
Reply
@mayurpatel • Reputation: 16,057
TREAD WITH TREND in GRANULESGRANULESTrade entered: Sell GRANULES @150.45 Target@140...
HIT 140------------------------
1
reply
Reply
@vijayjaria • Reputation: -7,514
#JustIn | Granules India board approves share buyback of up to 1.25 cr equity shares worth Rs 250 cr at Rs 200/sh
Like
reply
Reply
@ravikanthchopperla • Reputation: 11,889
BRIEF-Granules India Says US FDA Issues 3 Observations To Unit's Facility - Reuters
20-Jan-2020 03:03:46 PM
Jan 20 (Reuters) - Granules India Ltd GRAN.NS:
US FDA HAS COMPLETED INSPECTION OF THE FACILITY OF GRANULES PHARMACEUTICALS, INC.
US FDA HAS COMPLETED INSPECTION WITH THREE ...
Read more...
1
reply
Reply
@konartradetalk • Reputation: 35,743
💠💠
YOUR FREE EQUITY CASH CALL FOR THIS FORUM TODAY:
BUY GRANULS AT THE VERY BEGINING
STRICT STOP LOSS - 143
1ST TARGET - 146.20
2ND TARGET - 147
3RD TARGET - 147.75
## GO WITH SAFER QUANTITY ##
Disclaimer: All my Views/Suggestions/Calls are for Education Purpose Only. Please co...
Read more...
Like
reply
Reply
@ShoyabHafeji • Reputation: 1,144
HALAL INVESTMENT in GRANULESGRANULES 91 TO 131+ IF HV HOLD FOR 138/145+
GRANULES 146.50
HOLD ON
Like
reply
Reply
@ravikanthchopperla • Reputation: 11,889
Karvy CMD Parthasarathy resigns as Independent Director of Granules India Board
C Parthasarathy, Chairman and Managing Director of the Hyderabad-based Karvy Group, has
C Parthasarathy, Chairman and Managing Director of the Hyderabad-based Karvy Group, has
article wn
2
reply
Reply
@invictotrader • Reputation: 2,665
Granules India receives US FDA's ANDA approval for Loratadine Tablets
Like
reply
Reply
@invictotrader • Reputation: 2,665
Granules India share price rises 1% on stake sale in Chinese JV The conclusion of the transaction is subject to the fulfillment of certain closing conditions and regulatory approvals.
Like
reply
Reply
@ravikanthchopperla • Reputation: 11,889
Granules India formed an agreement with Hubei Biocause Heilen Pharmaceutical company to sell 3.3 crore equity shares worth RMB 109M held by its joint venture partner, Granules-Biocause Pharmaceutical Co. Limited.
1
reply
Reply
@ravikanthchopperla • Reputation: 11,889
GRANULES INDIA LTD - FDA MADE TWO OBSERVATIONS
Like
reply
Reply
- NewsBotFeb 13 6:08 PMGranules India gets tentative nod from USFDA for expectorant tabletsMoneycontrolNewsBotFeb 11 9:28 PMGranules India gets tentative nod from USFDA for generic Colchicine capsulesMoneycontrolNewsBotFeb 6 4:33 PMGranules Pharmaceuticals, Inc gets USFDA nod for Colchicine tabletsMoneycontrolNewsBotFeb 6 3:43 PMGranules India hits 52-week high after USFDA approvalMoneycontrolNewsBotFeb 5 4:43 PMGranules India share price jumps 5% on USFDA nod for antiviral medicineMoneycontrolNewsBotFeb 5 4:23 PMGranules India arm gets USFDA nod for Valganciclovir hydrochloride oral solutionMoneycontrolNewsBotFeb 4 5:28 PMGranules India divests entire stake in Granules-Biocause PharmaceuticalMoneycontrolNewsBotJan 28 7:33 PMQ3 earnings mixed so far; brokerages maintain 'buy' on 10 stocks with 9-23% upsideMoneycontrolNewsBotJan 28 3:23 PMSmall & midcaps back in spotlight as FIIs raise stake in 122 BSE companiesMoneycontrolNewsBotOct 22 6:58 PM
Granules India zooms 14% after Q2 profit of Rs 96 cr, USFDA nod for allergy drugMoneycontrol
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.